Evidence map›Paper›PMID 29588318›Full record

ArticleCancer immunology research2018

Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.

Takemasa Tsuji, Akira Yoneda, Junko Matsuzaki, Anthony Miliotto, Courtney Ryan, Richard C Koya, Kunle Odunsi

Abstract read
In one paragraph

Article in Cancer immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. CRISPR-Cas9 applications in T cells and adoptive T cell therapies.Cellular & molecular biology letters · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. WHSC1/NSD2 regulates immune infiltration in prostate cancer.Journal for immunotherapy of cancer · 2021
    Article
  11. Article
  12. Article
  13. Viral Vectors in Gene Therapy.Diseases (Basel, Switzerland) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takemasa TsujiCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Akira YonedaCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Junko MatsuzakiCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Anthony MiliottoCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Courtney RyanCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Richard C KoyaCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
Kunle OdunsiCenter for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York. kunle.odunsi@roswellpark.org.

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA159981
6 · The paper itself

Abstract

T cells genetically engineered with tumor antigen-specific T-cell receptor (TCR) genes have demonstrated therapeutic potential in patients with solid tumors. In order to achieve broader application, an efficient method to identify TCR genes for an array of tumor antigens and HLA restriction elements is required. Here, we have developed a method to construct a TCR-expression library from specimens, including frozen tumor biopsies, that contain antigen-specific T cells. TCR-expressing cassettes were constructed and cloned in a retroviral plasmid vector within 24 hours by unbiased PCR amplification of TCR α and β chain variable regions assembled with TCR constant regions. The method was validated by constructing TCR-expressing vectors from tumor antigen-specific T-cell clones and functionally assessing TCR gene-transduced T cells. We applied this method to frozen ovarian tumor specimens that were infiltrated by tumor antigen-specific T cells. The tumor-derived TCR libraries were expressed in peripheral T cells from healthy volunteers and screened for tumor antigen-specific TCR pairs with the use of an MHC/peptide tetramer reagent. Tumor antigen-specific TCR-expressing transgenes were recovered from isolated tetramer-positive T cells. Peripheral T cells that were engineered with library-derived TCR gene showed potent therapeutic antitumor effect in a tumor xenograft model. Our method can efficiently and rapidly provide tumor-specific TCR-expressing viral vectors for the manufacture of therapeutic and personalized antitumor T-cell products.

Indexed as

Gene LibraryAnimalsAntigens, NeoplasmCell EngineeringCells, CulturedCloning, MolecularFemaleFrozen SectionsGenetic TherapyGenetic VectorsHumansImmunotherapy, AdoptiveJurkat CellsMiceMice, Inbred NODMice, SCIDAntigens, NeoplasmReceptors, Antigen, T-Cell

Identifiers

PMID29588318
PMCPMC5932240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.